Phase 3 Multiple Sclerosis Trial, Recruiting NCT06408259 Sponsor: Bristol-Myers Squibb Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 3 Multiple Sclerosis Trial, Recruiting

NCT06408259
Recruiting Phase 3 🇦🇺 Australian site

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • You have been diagnosed with relapsing-remitting multiple sclerosis (MS), meaning your MS comes in episodes or "attacks" followed by periods of recovery, confirmed using 2017 diagnostic guidelines.
  • You have had at least 1 MS attack/relapse in the past year, OR at least 2 MS attacks/relapses in the past 2 years, OR a recent brain scan (MRI) within the last 6 months showed signs of active inflammation in the brain or spine.
  • Your level of disability, as measured by a standard MS scoring scale (EDSS), falls between 0 and 5.5, meaning anywhere from no disability to moderate disability affecting walking.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • You have a form of MS that is progressive (such as primary or secondary progressive MS), rather than relapsing-remitting.
  • You have another active or long-term condition affecting your immune system, separate from MS.
  • You have a significant ongoing condition affecting your heart, liver, nervous system, or another major body system.
  • There are additional criteria not listed here that the trial team will check (confirm with trial site).

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Australian sites

Royal Children's Hospital, Melbourne, Victoria
6139455661

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
8 April 2025
Est. completion
11 April 2031

Where this trial is recruiting

🇦🇺 Australia 🇮🇹 Italy 🇲🇽 Mexico 🇵🇱 Poland 🇵🇹 Portugal Puerto Rico 🇷🇴 Romania 🇪🇸 Spain 🇹🇼 Taiwan Turkey (Türkiye) 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Annualized relapse rate (ARR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov